Fischer Medical Ventures Limited’s (formerly known as Fischer Chemic Limited) wholly owned subsidiary – Time Medical International Ventures (India) Private Limited, and a Singapore-based company Nervotec Pte Ltd (Nervotec), firm up global partnership to revolutionize healthcare screening through contactless video-based vital signs monitoring..

Fischer Medical Ventures Limited（原名Fischer Chemic Limited）的全资子公司Time Medical International Ventures（India）Private Limited，以及一家总部位于新加坡的公司Nervotec Pte Ltd（Nervotec），建立了全球合作伙伴关系，通过基于非接触视频的生命体征监测彻底改变医疗筛查。。

Fischer Medical Ventures Limited (Fischer MVL) is renowned for its pioneering efforts in manufacturing high-quality Magnetic Resonance Imaging (MRI) systems in India, making them the first company to indigenously manufacture such advanced medical imaging equipment in India. Aside from medical imaging, Fischer MVL also carry a diverse portfolio of breakthrough diagnostic solutions, where Nervotec’s innovative health screening without any contact or wearables needed, fits in perfectly.

Fischer Medical Ventures Limited（Fischer MVL）以其在印度制造高质量磁共振成像（MRI）系统的开创性努力而闻名，使其成为印度第一家本土制造此类先进医疗成像设备的公司。除了医学成像之外，Fischer MVL还提供多种突破性诊断解决方案，Nervotec的创新健康筛查不需要任何接触或可穿戴设备，非常适合。

Fischer MVL is pleased to seal the strategic partnership with Nervotec to market their paradigm shifting technology globally..

Fischer MVL很高兴与Nervotec建立战略合作伙伴关系，在全球推广其范式转换技术。。

Nervotec is a Singapore-based company that empowers predictive healthcare via its contactless solution without wearables. Nervotec’s innovative solution uses remote photoplethysmography (rPPG) technology and artificial intelligence to measure physiological biomarkers such as heart rate, heart rate variability, respiration rate, oxygen saturation, stress scores and even blood pressure just from a person’s face using any camera-enabled device like smartphone, laptop, or tablet.

Nervotec是一家总部位于新加坡的公司，通过其无需穿戴设备的非接触式解决方案实现预测性医疗保健。Nervotec的创新解决方案使用远程光体积描记术（rPPG）技术和人工智能来测量生理生物标志物，例如心率，心率变异性，呼吸频率，血氧饱和度，压力评分甚至血压，只需使用智能手机，笔记本电脑或平板电脑等任何支持相机的设备即可从人的脸上测量。

Users simply had to look at their camera-enabled device and within minutes, Nervotec’s algorithms will analyze his/her vitals, making wearables or invasive procedures redundant. Clinically validated in Singapore, Nervotec’s process is fast, accurate, and cost effective, a ground-breaking solution to enable large scale screening for early detection and intervention..

用户只需查看他们的摄像头设备，几分钟内，Nervotec的算法就会分析他/她的生命体征，这使得可穿戴设备或侵入性程序变得多余。在新加坡进行临床验证后，Nervotec的过程快速，准确且具有成本效益，是一种开创性的解决方案，可以进行大规模筛查以进行早期发现和干预。。

Continuing to push the boundaries, Nervotec made a first-in-the-world breakthrough achievement recently by including clinically validated hemoglobin measurement (to measure Anaemia and detect Thalassemia) and HbA1C (average glucose level over a period) measurements as part of its comprehensive health monitoring capabilities.

Nervotec继续努力，最近取得了世界上第一个突破性成就，将经过临床验证的血红蛋白测量（用于测量贫血和检测地中海贫血）和HbA1C（一段时间内的平均血糖水平）测量作为其综合健康监测能力的一部分。

What used to require vials of blood & significant time to analyse, Nervotec made it possible with its contactless technology and give results within few minutes..

Nervotec过去需要大量的血液和大量的分析时间，它的非接触式技术使其成为可能，并在几分钟内给出结果。。

Mr. Ravindran Govindan, Executive Chairman & MD of Fischer MVL, expressed his enthusiasm about the collaboration: “We are elated to partner with Nervotec, a pioneer and leader in contactless vital signs monitoring that will redefine healthcare delivery worldwide. Not everyone has wearables, but most of us have a camera phone to enable Nervotec’s technology for regular monitoring of their own health and support mass screening faster and more cost effective.

Fischer MVL执行主席兼总经理拉文德兰·戈文丹先生对此次合作表示了热情：“我们很高兴与Nervotec合作，Nervotec是非接触式生命体征监测的先驱和领导者，将重新定义全球医疗服务。并非每个人都有可穿戴设备，但我们大多数人都有照相手机，使Nervotec的技术能够定期监测自己的健康状况，并支持更快、更具成本效益的大规模筛查。

We are excited about the potential of rPPG technology beyond HbA1C to.

我们对rPPG技术超越HbA1C的潜力感到兴奋。

detect irregular heartbeats and detection of cardiovascular disease, combined with blood pressure and blood sugar levels to determine the overall health of individuals worldwide. Nervotec’s solutions complement our portfolio of medical devices and diagnostic solutions, and will create great value for our customers and stakeholders.”.

检测不规则心跳和心血管疾病，结合血压和血糖水平来确定全球个人的整体健康状况。Nervotec的解决方案补充了我们的医疗设备和诊断解决方案组合，并将为我们的客户和利益相关者创造巨大的价值。”。

Mr. Jonathan Lau, Co-founder and CEO of Nervotec, emphasized the transformative potential of their technology, “With the high prevalence of undetected conditions such as hypertension and diabetes, we believe Nervotec’s innovative solution can truly make a difference in the well-being of billions of people globally.

Nervotec联合创始人兼首席执行官乔纳森·刘先生强调了他们技术的变革潜力，“由于高血压和糖尿病等未被发现的疾病患病率很高，我们相信Nervotec的创新解决方案可以真正改变全球数十亿人的福祉。

By identifying health risks before they escalate, Nervotec’s technology empowers individuals, healthcare providers, and employers to take timely action. This partnership with Fischer MVL enables us to expand our reach and deliver impactful health insights across various sectors, from workplace safety to personalized healthcare.”.

通过在健康风险升级之前识别健康风险，Nervotec的技术使个人、医疗保健提供者和雇主能够及时采取行动。与Fischer MVL的这种合作关系使我们能够扩大我们的影响力，并在各个部门提供有影响力的健康见解，从工作场所安全到个性化医疗保健。”。

This strategic alliance combines Fischer MVL’s expertise in medical devices and solutions, robust resources, and strategic network worldwide with Nervotec’s cutting-edge technologies that promise to redefine healthcare delivery globally.

该战略联盟将Fischer MVL在医疗设备和解决方案方面的专业知识、强大的资源和全球战略网络与Nervotec的尖端技术相结合，有望在全球范围内重新定义医疗保健服务。